E-LIB Suche - Ergebnisse für: Acosta, Edward P.

1

Population Pharmacokinetic Modeling of Abacavir/Dolutegravi..:

Chandasana, Hardik ; van Dijkman, Sven C. ; Mehta, Rashmi...
Infectious Diseases and Therapy. 13 (2024) 8 - p. 1877-1891 , 2024

Link: https://doi.org/10.1007/..

2

Pharmacokinetic variability of CFTR modulators from standar..:

Rose, Natalie R. ; Chalamalla, Ashritha R. ; Garcia, Bryan A....
Pulmonary Pharmacology & Therapeutics. 86 (2024) - p. 102301 , 2024

Link: https://doi.org/10.1016/..

3

Differential distribution of ivacaftor and its metabolites ..:

Liu, Zhongyu ; Anderson, Justin D. ; Rose, Natalie R....
Pulmonary Pharmacology & Therapeutics. 86 (2024) - p. 102314 , 2024

Link: https://doi.org/10.1016/..

4

HIV post-treatment controllers have distinct immunological ..:

Etemad, Behzad ; Sun, Xiaoming ; Li, Yijia...
Proceedings of the National Academy of Sciences. 120 (2023) 11 - p. , 2023

Link: https://doi.org/10.1073/..

5

Population Pharmacokinetic Modeling of Dolutegravir to Opti..:

Chandasana, Hardik ; Thapar, Mita ; Hayes, Siobhan...
Clinical Pharmacokinetics. 62 (2023) 10 - p. 1445-1459 , 2023

Link: https://doi.org/10.1007/..

6

A phase I/II study of preoperative letrozole, everolimus, a..:

Vaklavas, Christos ; Stringer-Reasor, Erica M. ; Elkhanany, Ahmed M....
Breast Cancer Research and Treatment. 198 (2023) 2 - p. 217-229 , 2023

Link: https://doi.org/10.1007/..

7

Routine use of low-dose glucarpidase following high-dose me..:

Schaff, Lauren R. ; Lobbous, Mina ; Carlow, Dean...
BMC Cancer. 22 (2022) 1 - p. , 2022

Link: https://doi.org/10.1186/..

8

Ivacaftor-elexacaftor-tezacaftor and tacrolimus combination..:

Smith, Megan ; Ryan, Kevin J. ; Gutierrez, Hector...
Journal of Cystic Fibrosis. 21 (2022) 1 - p. e8-e10 , 2022

Link: https://doi.org/10.1016/..

9

Quantitation of cystic fibrosis triple combination therapy,..:

Ryan, Kevin J. ; Guimbellot, Jennifer S. ; Dowell, Alexander E....
Journal of Chromatography B. 1213 (2022) - p. 123518 , 2022

Link: https://doi.org/10.1016/..

10

Plasma and cellular ivacaftor concentrations in patients wi..:

Guimbellot, Jennifer S. ; Ryan, Kevin J. ; Anderson, Justin D....
Pediatric Pulmonology. 57 (2022) 11 - p. 2745-2753 , 2022

Link: https://doi.org/10.1002/..

11

Systemic Administration of a Brain Permeable Cdk5 Inhibitor..:

Umfress, Alan ; Singh, Sarbjit ; Ryan, Kevin J....
Frontiers in Pharmacology. 13 (2022) - p. , 2022

Link: https://doi.org/10.3389/..

12

Pharmacokinetics, safety, tolerability, and antiviral activ..:

Ruel, Theodore D ; Acosta, Edward P ; Liu, Jessica P...
The Lancet HIV. 9 (2022) 5 - p. e332-e340 , 2022

Link: https://doi.org/10.1016/..

13

An open-label, pilot study of veliparib and lapatinib in pa..:

Stringer-Reasor, Erica M. ; May, Jori E. ; Olariu, Eva...
Breast Cancer Research. 23 (2021) 1 - p. , 2021

Link: https://doi.org/10.1186/..

14

A Phase 1/2 Randomized, Placebo-Controlled Trial of Romides..:

McMahon, Deborah K ; Zheng, Lu ; Cyktor, Joshua C...
The Journal of Infectious Diseases. 224 (2020) 4 - p. 648-656 , 2020

Link: https://doi.org/10.1093/..

15

Variable cellular ivacaftor concentrations in people with c..:

Guimbellot, Jennifer S. ; Ryan, Kevin J. ; Anderson, Justin D....
Journal of Cystic Fibrosis. 19 (2020) 5 - p. 742-745 , 2020

Link: https://doi.org/10.1016/..